IGC Pharma secures Canadian patent for Alzheimer's agitation drug candidate
IGC•IGC Pharma secured a Canadian patent covering the composition of IGC-AD1, its investigational oral therapy for agitation in Alzheimer's disease. The candidate now has five granted patents and 10 applications pending worldwide; its Phase 2 CALMA trial completed enrollment in September 2026 and is in its final dosing period.
1. Patent and trial update
The Canadian patent extends protection for IGC-AD1 within the same patent family across the U.S., Canada and Mexico. The Phase 2 CALMA trial completed enrollment in September 2026 and is in its final dosing period; topline results will follow database lock and unblinding.
